Black-Owned Digital Health Company Acclinate Raises $7M To Make Clinical Trials More Inclusive
Acclinate, a Birmingham, Alabama-based healthcare technology company, has completed a $7 million Series A funding round.
The funding round, led by Cencora Ventures and supported by Labcorp and Latimer Ventures, aimed to enhance Acclinate’s efforts to promote health equity and transform the inclusivity of clinical trials.
Transforming Clinical Trials through Trust and Technology
Acclinate’s strategy aims to build trust and foster long-term relationships with diverse communities.
Their digital platform, NOWINCLUDED, is designed to educate and engage underrepresented groups in clinical trials, ensuring their inclusion in medical research.
The platform serves as an educational tool while creating a welcoming environment for participants to discuss and learn about healthcare issues pertinent to their communities.
Leveraging Data for Inclusive Medical Research
Acclinate’s use of data and analytics is important in clinical trials. Their e-DICT (Enhanced Diversity in Clinical Trials) platform employs predictive analytics to understand community responses to clinical trials.
This allows for more inclusive trial planning and execution, ensuring that trials represent diverse populations.
These types of data-driven insights are needed to refine strategies for connecting with and enrolling participants from varied backgrounds, enhancing the overall quality and applicability of research findings.
Impacts of the Funding on Healthcare and Pharma
The influx of $7 million in funding will increase Acclinate’s growth and refine its data-driven approaches to clinical trials.
“This investment marks a significant milestone for Acclinate and underscores our commitment to revolutionizing health equity and clinical trial diversity at a larger scale,” said Del Smith, CEO and Co-Founder of Acclinate.
“With the backing of prominent healthcare organizations like Cencora and LabCorp, we are poised to accelerate tangible change in the healthcare industry and empower diverse communities to proactively manage their health.”
This advancement will benefit patients from diverse backgrounds by increasing their representation in medical research and aid pharmaceutical companies.
By enabling a more inclusive clinical trial landscape, Acclinate helps companies access a broader data pool, leading to the development of treatments that are effective across diverse populations.
